Advertisement
Mayo Clinic Proceedings Home

Prostate Cancer Ki-67 (MIB-1) Expression, Perineural Invasion, and Gleason Score as Biopsy-Based Predictors of Prostate Cancer Mortality: The Mayo Model

Published:February 03, 2014DOI:https://doi.org/10.1016/j.mayocp.2013.12.001

      Abstract

      Objective

      To determine the role of cellular proliferation and other biopsy-based features in the prediction of prostate cancer mortality.

      Patients and Methods

      Between 1993 and 2012, our institution has performed quantitation of prostate cancer DNA ploidy and Ki-67 (MIB-1) on most prostate cancer needle biopsy specimens. The outcomes of 451 consecutive patients with biopsy-proven cancer treated by radical prostatectomy between January 24, 1995, and December 29, 1998, without neoadjuvant hormonal therapy were assessed. Clinical and biopsy information obtained before radical prostatectomy was placed in multivariate Cox proportional hazards regression models to predict local or systemic progression and cancer-specific death. Predictive ability was evaluated using a concordance index.

      Results

      With a median follow-up of 12.9 years, 46 patients experienced local or systemic progression, and 18 patients died of prostate cancer. On multivariate analysis, the biopsy features of Ki-67 expression, perineural invasion, and Gleason score were associated with local or systemic progression. Ki-67 expression, perineural invasion, and Gleason score were associated with cancer-specific death with a concordance index of 0.892. After adjusting for perineural invasion and Gleason score, each 1% increase in Ki-67 expression was associated with a 12% increased risk of cancer-specific death (P<.001). Ki-67 expression alone was a strong predictor of cancer-specific outcomes and improved the predictive ability of currently used algorithms.

      Conclusion

      This study documents that long-term prostate cancer outcomes are best estimated with a combination of Gleason score, perineural invasion, and Ki-67 expression. Given its low cost, rapid assessment, and strong predictive power, we believe that adding Ki-67 expression to perineural invasion and Gleason score at biopsy should be considered a standard by which all new biomarkers are compared before introducing them into clinical practice.

      Abbreviations and Acronyms:

      BCF (biochemical failure), c-index (concordance index), HR (hazard ratio), PSA (prostate-specific antigen), RP (radical prostatectomy)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Siegel R.
        • Ward E.
        • Hao Y.
        • Xu J.
        • Thun M.J.
        Cancer statistics, 2009.
        CA Cancer J Clin. 2009; 59: 225-249
        • Inman B.A.
        • Davies J.D.
        • Rangel L.J.
        • et al.
        Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
        Cancer. 2008; 113: 1544-1551
        • Boorjian S.A.
        • Karnes R.J.
        • Rangel L.J.
        • Bergstralh E.J.
        • Blute M.L.
        Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
        J Urol. 2008; 179: 1354-1360
        • Roach III, M.
        • Bae K.
        • Speight J.
        • et al.
        Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
        J Clin Oncol. 2008; 26: 585-591
        • Pilepich M.V.
        • Winter K.
        • Lawton C.A.
        • et al.
        Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290
        • Bill-Axelson A.
        • Holmberg L.
        • Ruutu M.
        • et al.
        Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer.
        N Engl J Med. 2005; 352: 1977-1984
        • Widmark A.
        • Klepp O.
        • Solberg A.
        • et al.
        • Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3
        Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial [published correction appears in Lancet. 2009;373(9670):1174].
        Lancet. 2009; 373: 301-308
        • Feigenberg S.J.
        • Lee W.R.
        • Desilvio M.L.
        • et al.
        Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
        Int J Radiat Oncol Biol Phys. 2005; 62: 956-964
        • Fransson P.
        • Lund J.A.
        • Damber J.E.
        • et al.
        • Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3
        Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
        Lancet Oncol. 2009; 10: 370-380
        • Hu J.C.
        • Elkin E.P.
        • Pasta D.J.
        • et al.
        Predicting quality of life after radical prostatectomy: results from CaPSURE.
        J Urol. 2004; 171: 703-707
        • Berney D.M.
        • Gopalan A.
        • Kudahetti S.
        • et al.
        Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.
        Br J Cancer. 2009; 100: 888-893
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • Stephenson A.J.
        • Scardino P.T.
        • Eastham J.A.
        • et al.
        Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy [published correction appears in J Natl Cancer Inst. 2012;104(5):423].
        J Natl Cancer Inst. 2006; 98: 715-717
        • Stephenson A.J.
        • Kattan M.W.
        • Eastham J.A.
        • et al.
        Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
        J Clin Oncol. 2009; 27: 4300-4305
        • Kattan M.W.
        • Potters L.
        • Blasko J.C.
        • et al.
        Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer.
        Urology. 2001; 58: 393-399
        • Cagiannos I.
        • Karakiewicz P.
        • Eastham J.A.
        • et al.
        A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
        J Urol. 2003; 170: 1798-1803
        • Thompson I.M.
        • Canby-Hagino E.
        • Lucia M.S.
        Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor [editorial].
        J Natl Cancer Inst. 2005; 97: 1236-1237
        • Tollefson M.K.
        • Karnes R.J.
        • Rangel L.J.
        • Bergstralh E.J.
        • Boorjian S.A.
        The impact of clinical stage on prostate cancer survival following radical prostatectomy.
        J Urol. 2013; 189: 1707-1712
        • Fluge Ø.
        • Gravdal K.
        • Carlsen E.
        • et al.
        • Norwegian Gastrointestinal Cancer Group
        Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.
        Br J Cancer. 2009; 101: 1282-1289
        • Walts A.E.
        • Bose S.
        p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia.
        Hum Pathol. 2009; 40: 957-964
        • Viale G.
        • Giobbie-Hurder A.
        • Regan M.M.
        • et al.
        • Breast International Group Trial 1-98
        Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
        J Clin Oncol. 2008; 26: 5569-5575
        • Wangsa D.
        • Ryott M.
        • Avall-Lundqvist E.
        • et al.
        Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma.
        Br J Cancer. 2008; 99: 1121-1128
        • Viale G.
        • Regan M.M.
        • Mastropasqua M.G.
        • et al.
        • International Breast Cancer Study Group
        Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
        J Natl Cancer Inst. 2008; 100: 207-212
        • Determann O.
        • Hoster E.
        • Ott G.
        • et al.
        • European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group
        Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
        Blood. 2008; 111: 2385-2387
        • Tollefson M.K.
        • Thompson R.H.
        • Sheinin Y.
        • et al.
        Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.
        Cancer. 2007; 110: 783-790
        • Sebo T.J.
        • Cheville J.C.
        • Riehle D.L.
        • et al.
        Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
        Am J Surg Pathol. 2002; 26: 431-439
        • Khor L.Y.
        • Bae K.
        • Paulus R.
        • et al.
        MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
        J Clin Oncol. 2009; 27: 3177-3184
        • Berger A.P.
        • Spranger R.
        • Kofler K.
        • Steiner H.
        • Bartsch G.
        • Horninger W.
        Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
        Prostate. 2003; 57: 93-98
        • Sebo T.J.
        • Cheville J.C.
        • Riehle D.L.
        • et al.
        Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
        Cancer. 2001; 91: 2196-2204
        • Sebo T.J.
        Digital image analysis.
        Mayo Clin Proc. 1995; 70: 81-82
        • Harrell Jr., F.E.
        • Lee K.L.
        • Mark D.B.
        Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
        Stat Med. 1996; 15: 361-387
        • Liebig C.
        • Ayala G.
        • Wilks J.A.
        • Berger D.H.
        • Albo D.
        Perineural invasion in cancer: a review of the literature.
        Cancer. 2009; 115: 3379-3391
        • Lee I.H.
        • Roberts R.
        • Shah R.B.
        • Wojno K.J.
        • Wei J.T.
        • Sandler H.M.
        Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1059-1064
        • Harnden P.
        • Shelley M.D.
        • Clements H.
        • et al.
        The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.
        Cancer. 2007; 109: 13-24
        • Warth A.
        • Fink L.
        • Fisseler-Eckhoff A.
        • et al.
        • Pulmonary Pathology Working Group of the German Society of Pathology
        Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids.
        Virchows Arch. 2013; 462: 507-513
        • Gudlaugsson E.
        • Skaland I.
        • Janssen E.A.
        • et al.
        Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.
        Histopathology. 2012; 61: 1134-1144
        • Allsbrook Jr., W.C.
        • Mangold K.A.
        • Johnson M.H.
        • Lane R.B.
        • Lane C.G.
        • Epstein J.I.
        Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist [published correction appears in Hum Pathol. 2001;32(12):1417].
        Hum Pathol. 2001; 32: 81-88
        • Glaessgen A.
        • Hamberg H.
        • Pihl C.G.
        • Sundelin B.
        • Nilsson B.
        • Egevad L.
        Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens.
        Virchows Arch. 2004; 445: 17-21
        • Smith Jr., J.A.
        • Scardino P.T.
        • Resnick M.I.
        • Hernandez A.D.
        • Rose S.C.
        • Egger M.J.
        Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial.
        J Urol. 1997; 157: 902-906